Pathology: ALL Flashcards
These are using CLIs and Pathology information
What is the pathophysiology of atherosclerosis?
- Chronic stress on the endothelium (e.g., due to arterial hypertension and turbulence)
- Endothelial cell dysfunction, which leads to:
- Invasion of inflammatory cells (mainly monocytes and lymphocytes) through the disrupted endothelial barrier
- Adhesion of platelets to the damaged vessel wall
- PDGF stimulates the migration and proliferation of smooth muscle cells (SMCs) in the tunica intima and mediates the differentiation of fibroblasts into myofibroblasts - Inflammation of the vessel wall
- Macrophages and SMCs ingest cholesterol from oxidized LDL and transform into foam cells (macrophages filled with lipid droplets).
- Foam cells accumulate to form fatty streaks (early atherosclerotic lesions).
- Lipid-laden macrophages and SMCs produce extracellular matrix (e.g., collagen) deposition → development of a fibrous plaque (atheroma)
- Inflammatory cells in the atheroma (e.g., macrophages) cause → weakening of the fibrous cap of the plaque due to the breakdown of extracellular matrix → minor stress ruptures the fibrous cap
- Calcification of the intima
- Plaque rupture → exposure of thrombogenic material (e.g., collagen) → thrombus formation with vascular occlusion or spreading of thrombogenic material
What are the histopathology findings in MI
- Gross and microscopic
What is the difference between a STEMI and a NSTEMI
Coronary artery occlusion
Partial coronary artery occlusion
Decreased myocardial blood flow → supply-demand mismatch → myocardial ischemia
Usually affects the inner layer of the myocardium (subendocardial infarction)
Typically manifests clinically as unstable angina and/or NSTEMI
Complete coronary artery occlusion
Impaired myocardial blood flow → sudden death of myocardial cells (if no reperfusion occurs)
Usually affects the full thickness of the myocardium (transmural infarction)
Typically manifests clinically as STEMI
Etiology of Athlerosclerosis
Traditional ASCVD risk factors
Nonmodifiable risk factors
Advancing age
Male sex
Race and ethnicity
Modifiable risk factors
Smoking
Diabetes mellitus
Hypertension
Dyslipidemia (↑ total cholesterol, ↓ HDL cholesterol)
What is the general pathogenesis of IHD
- increase need for O2 or a decreased supply of O2.
- Pathogenesis
- Lack of blood supply, decreased O2, therefore decreased ATP, Loss of myocyte
- function, cell swelling Ischemia (1-2min) then progress
- to Necrosis (20-40min). Inflam. (Neutrophils, Macrophages, Healing, Scar)
Comlications of MI acute and long term
0-24 hours
Sudden cardiac death
Arrhythmias (e.g., ventricular fibrillation)
Acute heart failure → pulmonary edema
Cardiogenic shock
1-3 days
Fibrinous pericarditis
3-14 days
Papillary muscle ischemia or rupture → mitral regurgitation
Interventricular septal defect → acute VSD (left to right shunt)
Ventricular free wall rupture → cardiac tamponade
Ventricular pseudoaneurysm
2 weeks +
True ventricular aneurysm → mural thrombus
Dressler pericarditis
Arrhythmias (e.g., AV block)
Congestive heart failure
Reinfarction
This is a slide showing cardiac myocytes: what stage of MI is this and what miscroscopic features are seen? What gross morphology would be present?
acute phase. in the first few hours. the dead myocytes still have nucleus but they have pyknosis (darkening) and smaller. there are few fibrosis (normal). there is leakage of blood keeping some tissue alive. increase RBC. Acute MI <24 h shows contraction bands being made.
GROSS: Normal in the first 4 hours, after will show a dark red area where infart occured
This is a slide showing cardiac myocytes: what stage of MI is this and what miscroscopic features are seen? What gross morphology would be present?
After inflammatory period- increased macrophages eating dead cells. no nucleus in myocytes. haemorrhage and inflammation clearing and being replaced by macrophages. Replaced by granulation tissue- then granulation tissue replaced by collagen bundles
GROSS: Dark red area, (at the 2 week mark there will be a yellow centre with red boarders.
This is a slide showing cardiac myocytes: what stage of MI is this and what miscroscopic features are seen? What gross morphology would be present?
Elongated cells (fibroblasts) are starting to replace dead cardiomyocytes. The process of granulation tissue forming also includes sprouting capillaries and inflammatory cells (lymphocytes, macrophages).
Necrosis is occuring and macrophages and lymphocytes are phagocytosing dead cells.
This process is typical of the granulation stage, which begins approximately two weeks after necrosis development.
GROSS: Yellow centre with red boarder.
Total replacement of dead cells by scar tissue. band of scar tissue and rest of myocardial tissue. white tissue is collagen bundles (scar tissue).
This is a slide showing cardiac myocytes: what stage of MI is this and what miscroscopic features are seen? What gross morphology would be present?
Total replacement of dead cells by scar tissue. band of scar tissue and rest of myocardial tissue. white tissue is collagen bundles (scar tissue).
SLIDE SHOWS: Healthy myocardium (left side) and myocardial scarring (most of the right side) are visible. The scar tissue appears white-grey because of fibrosis and loss of cardiomyocytes.
GROSS: Small white scar
What features are seen on a microscopy of a vessel which shows athlerosclerosis?
there is damage in lumen where thickening is occurring and increased macrophages- leakage of fat. as lesion increases in size, it will develop bigger plaques. increased proliferation of cap creating fibrosis cap.
What is the lipid deposition pathway
Chylomicrons: large triglyceride rich particles made by the intestine, which are involved in the transport of dietary triglycerides and cholesterol to peripheral tissues and liver.
LVDLP: produced by the liver and are triglyceride rich.
ILDL: removal of triglycerides from VLDL by muscle and adipose tissue results in the formation of IDL particles which are enriched in cholesterol
LDL: derived from VLDL and IDL particles and they are even further enriched in cholesterol. LDL carries the majority of the cholesterol that is in the circulation. - deposit in tissues
HDL: play an important role in reverse cholesterol transport from peripheral tissues to the liver, which is one potential mechanism by which HDL may be anti-atherogenic
mechanism of action, indications, contraindications, and side effects of lipid lowering medications: statins
MOA 1.Inhibit HMG CoA reductase which is the rate limiting enzyme in cholesterol synthesis in the liver, thereby ↓ the amount of cholesterol produced by the liver
2.Subsequently, liver cells respond to the decreased cholesterol concentration by activating the transcription factor Sterol Regulatory Element Binding Protein (SREBP) to ↑ LDL receptor expression on cells. Thus, ↑ cholesterol is extracted from blood and taken up into cells for storage or excretion. (Main effect)
Indications
Hypercholesterolemia, hyperlipidemia, high risk of CAD
Contraindications Pregnancy or breastfeeding, renal impairment
Side effects Mild: Myalgia, GI disturbance, raised concentration of liver enzymes (transaminase) in plasma, insomnia, rash
Serious, but rare: rhabdomyolysis, angioedema
mechanism of action, indications, contraindications, and side effects of lipid lowering medications: ezetimibe
Ezetimibe
MOA Inhibits the absorption of cholesterol from the duodenum by blocking transport protein NPC1L1 in the brush border of enterocytes, without affecting the absorption of fat-soluble vitamins, triglycerides or bile acids → ↓cholesterol concentration
Indications Hypercholesterolemia - with statin
Contraindications Breastfeeding
Side effects Diarrhoea, abdominal pain, headache, rash and angioedema
mechanism of action, indications, contraindications, and side effects of lipid lowering medications: Fibrates
Fibrates
MOA Fibrates are agonists at the nuclear receptor transcription factor PPARɑ → ↑expression of lipoprotein lipase and inhibits synthesis of apoprotein C-III which normally inhibits lipoprotein lipase. This increases lipolysis and the elimination of triglyceride rich particles from plasma.
This also causes a shift in the size/composition of LDL particles from small/dense to large, buoyant particles, which have greater affinity for the LDL receptor and are therefore catabolised more rapidly.
Indications Dyslipidemia
Contraindications Avoid use with statins
Also contraindicated if creatinine clearance is under 30 mL/min or if the patient has severe renal dysfunction.
Side effects Rhabdomyolysis (occurs in patients with renal impairment), GI symptoms, pruritus and rash, gallstones (only with clofibrate, due to increased bile production)
PCSK9 inhibitors
MOA PCSK9 is an enzyme that normally reduces the number of available LDL receptors on cells, mainly hepatocytes. Inhibitors (which are monoclonal antibodies) of this enzyme thereby ↑ the number of receptors, resulting in more LDL cholesterol being removed from circulation.
Indications In Australia, PCSK9 inhibitors have been approved for those with familial hypercholesterolemia who cannot lower blood cholesterol to certain levels with standard medications, or those who cannot tolerate standard medications
Contraindications Pregnancy
Route and frequency SC injection every 2-4 weeks
Desired effects Reduced LDL in blood flow due to increase in receptor availability
Side effects * Flu-like symptoms such as cold, nausea, back pain and joint pain
* soreness or itchiness at injection site
* muscle pain
mechanism of action, indications, contraindications, and side effects of lipid lowering medications: PCSK9 inhibitors
PCSK9 inhibitors
MOA PCSK9 is an enzyme that normally reduces the number of available LDL receptors on cells, mainly hepatocytes. Inhibitors (which are monoclonal antibodies) of this enzyme thereby ↑ the number of receptors, resulting in more LDL cholesterol being removed from circulation.
Indications In Australia, PCSK9 inhibitors have been approved for those with familial hypercholesterolemia who cannot lower blood cholesterol to certain levels with standard medications, or those who cannot tolerate standard medications
Contraindications Pregnancy
Side effects * Flu-like symptoms such as cold, nausea, back pain and joint pain
* soreness or itchiness at injection site
* muscle pain
Develop a differential diagnosis for acute chest pain and identify key aspects of a patient’s presentation that suggest each diagnosis.
DDX, type of pain, vital signs and one test result to confirm.
ACS (MI, unstable angina): central crushing chest pain, hypertension, raised troponins
Aortic dissection: central ripping pain, leg weakness, radioradial/ femoral delay, xray shows widenned mediastinum.
Pericarditis → cardiac tamponade: worse when lying flat, tachycardia and hypotensive, ECG shows spodics sign, and changing QRS height. follows infection.
PE: unilateral pleuric chest pain, tachypneic, pleural rub, right heart strain, d-dimer.
Pneumothorax: sharp ulilateral chest pain, Auscultation: breath sounds absent
Percussion: hyperresonance.
GORD: worse after eating food, especially spicy foods, relieved with PPI, normal vital signs.
Describe demographics, aetiology/pathophysiology, risk factors, clinical features (+ atypical presentations), investigation findings for an ACS
Demographics: M>F, >55 yr. Old
Aetiology/ pathophysiology
1. Atherosclerosis – most commonly
2. Coronary artery dissection.
3. Vasospasms
4. Myocarditis
5. Vasculitis
6. Global hypertension
7. Severe anaemia
8. Severe aortic stenosis
Risk Factors
Increasing age, Male gender, Pmhx of angina and/or known CAD, Family history of CAD, Diabetes mellitus, Systolic HTN, Smoking, Hyperlipidaemia, Alcohol, Stress, Poor diet/sedentary lifestyle
Clinical Features
- Chest pain – central crushing chest pain with radiation to left arm, shoulder, neck, jaw and/or epigastrum.
- Dyspnoea, pallor, nausea & vomiting, diaphoresis, anxiety, dizziness, light-headedness, syncope
- In diabetics, chest pain may be completely absent due to polyneuropathy
Investigation findings
Unstable Angina
* ECG= no ST elevation
* Troponin negative
NSTEMI
* ECG= ST depression +/- T wave inversion (no ST elevation)
* Troponin positive
STEMI
* ECG= ST elevation
* Anterior STEMI= V1-V4
* Inferior = II,III,aVF
* Lateral = V5-V6, I, aVL
Troponin Positive
Describe the complications (immediate and long term) of acute coronary syndrome.
Acute
cardiac failure and death – mostly to VF/VT
arrhythmias – 90% patients <24 hours
dead tissue stimulates inflammation
CHF – heart unable to support CO
cardiogenic shock (RV involvement)
pericarditis
mural thrombus formation
myocardial wall rupture tamponade
→ occur 3-7 days post MI Papillary muscle rupture → mitral regurgitation
Chronic
chronic IHD/ischaemic cardiomyopathy
result in CHF
arrhythmias
ventricular aneurysm
mural thrombus
papillary muscle contraction mitral reg
dilated cardiomyopathy
Outline the acute management of acute coronary syndrome
STEMI and NSTEMI
STEMI: reperfusion stabilisation
* Aspirin PO 300mg stat
* Clopidogrel
* Opioids (fentanyl)
* PCI if available within 90 minutes with unfractionated heparin
* Thrombolysis if PCI isn’t available
o Fibrinolytic agent with heparin
o Get patient to area with cath lab
* Consider admission to CCU
NSTEMI: plaque
* Aspirin PO 300mg stat
* Beta blockers
* Anti-platelet eg ticagrelor or clopidogrel
* Opioids
* Anticoagulant
* Nitrates
Compare the indications, contraindications and complications of percutaneous intervention and thrombolysis for management of ACS.
Percutaneous Coronary Intervention: utilising stents
contraindications: high risk of bleeding, hypercoaguability state, cannot withstand cardiac surgery.
complications: coronary artery injury/ rupture - renal failure, stroke, MI
Thrombolysis: break up and dissolve clot.
- used if chest pain cannot be PCI in first 90 min, or in rural setting.
- contraindications: prior intercranial hemorhhage, AD, high risk of bleeding.
- Complications: arrthymias, systemic bleeds.
Discuss the limitations of assessing and managing acute coronary syndrome in a rural setting.
Assessing
* Transport to hospital; delayed arrival to the hospital or delay in seeking hospital care
* Triage; may be delayed due to staffing
* Availability of equipment; blood forms, blood collection, ECG machines, drugs
* Availability of staffing; doctors or nurses
* Availability of diagnostic testing is limited
* Cultural and language difference may be a barrier to receiving information in the form of a history; may also impede examination
Managing
* Availability of PCI
* If thrombolysis is contraindicated and PCI is not available, the patient has to be transported to another facility where PCI is available. After 12 hours, the infarct may be complete.
* Availability of certain medications including pain relief
* Follow up of bloods/testing sent away